The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Colon cancer continues to be one of the leading causes of mortality and morbidity
throughout the world despite the availability of reliable screening tools and effective …

Purpose: Evaluate response of mismatch repair–deficient (dMMR) rectal cancer to
neoadjuvant chemotherapy. Experimental Design: dMMR rectal tumors at Memorial Sloan …

Colon cancer inter-tumour heterogeneity is installed on multiple levels, ranging from (epi)
genetic driver events to signalling pathway rewiring reflected by differential gene expression …

Studies have shown that the prevalence of RAS and BRAF mutations may differ by tumor
sidedness among metastatic colorectal cancer (mCRC) patients. Both mutation status and …

Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …

Objective: To analyze clinical outcomes and prognostic variables of patients undergoing
hepatic resection for BRAF mutant (BRAF-mut) colorectal liver metastases (CRLM) …

Colon cancer is one of the most frequently diagnosed malignancies in adults, considering
both its incidence and prevalence. Anatomically, the right colon is considered as being from …

CD73, a cell surface 5′ nucleotidase that generates adenosine, has emerged as an
attractive therapeutic target for reprogramming cancer cells and the tumor microenvironment …

Mismatch repair‐deficient (dMMR) and/or microsatellite instability‐high (MSI) colorectal
cancers (CRC) represent about 5% of metastatic CRC (mCRC). Prognosis and …